Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers.

Triple-negative breast cancers (TNBCs) are frequently recurrent due to the development of drug resistance post chemotherapy. Both the existing literature and our study found that surface receptor CD47 (cluster of differentiation 47) was upregulated in chemotherapy-treated TNBC cells. The goal of this study was to develop a monoclonal antibody (mAb)-based targeting strategy to treat TNBC after standard treatment.

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer.

Triple-negative breast cancers (TNBCs) are highly aggressive and recurrent. Standard cytotoxic chemotherapies are currently the main treatment options, but their clinical efficacies are limited and patients usually suffer from severe side effects. The goal of this study was to develop and evaluate targeted liposomes-delivered combined chemotherapies to treat TNBCs.

Natural male contraceptive: phytochemical investigation and anti-spermatogenic activity of Pistia stratiotes Linn.

This work is an attempt to explore the anti-spermatogenic activity of Pistia stratiotes and to investigate it as a male contraceptive. The prepared extracts were screened for the presence of alkaloids, glycosides, steroids, flavonoids, saponin and phenolic compounds. To assess the anti-spermatogenic activity, mice were orally administered with the various extracts of P.